Journal
ONCOGENE
Volume 33, Issue 38, Pages 4675-4684Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2014.69
Keywords
-
Funding
- National Research Foundation of Korea (NRF) grant [2012R1A5A1048236]
- Drug Target Validation program [20090093987]
- Bio & Medical Technology Development Program [2012M3A9B4028785]
- Redoxomics grant - Ministry of Science, ICT & Future Planning [2012M3A9C5048708]
- Ewha Womans University Research Grant
Ask authors/readers for more resources
We provide detailed mechanisms of Ahnak-mediated potentiation of transforming growth factor beta (TGF beta) signaling, which leads to a negative regulation of cell growth. We show that Smad3 interacts with Ahnak through MH2 domain and that Ahnak stimulates Smad3 localization into nucleus leading to potentiating TGF beta-induced transcriptional activity of R-Smad. Moreover, overexpression of Ahnak resulted in growth retardation and cell cycle arrest through downregulation of c-Myc and cyclin D1/D2. We describe results from analyses of Ahnak(-/-) mouse model expressing middle T antigen in a mammary gland-specific manner (MMTVTg/+ Ahnak(-/-)), which showed significantly progressed hyperplasia of mammary glands compared with MMTVTg/+ Ahnak(+/+). Finally, we screened multiple human breast cancer tissues and showed that the expression of Ahnak in cancer tissues is lower than that in control tissues by 50%. Taken together, these data indicate that Ahnak mediates a negative regulation of cell growth and acts as novel tumor suppressor through potentiation of TGF beta signaling.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available